Stock Events

Stock Events

Puma Biotechnology 

$8.82
64
-$0.01-0.11% 20:00 Today
+$0.01+0.11%22:30After hours

Statistics

Day High
8.97
Day Low
8.62
52W High
9.4
52W Low
4.3
Volume
189,175
Avg. Volume
310,914
Mkt Cap
455.29M
P/E Ratio
16.67
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.17
0.02
0.2
0.39
Expected EPS
0.09
Actual EPS
N/A

Financials

13.62%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
228.37MRevenue
31.11MNet Income

Analyst Ratings

6.00Average Price Target
The highest estimate is 6.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PBYI. It's not an investment recommendation.
Microsoft
10
MSFT
Realty Income
8
O
Amazon
8
AMZN
NVIDIA
8
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG competes in the oncology market, directly challenging Puma Biotechnology's cancer-focused treatments.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca operates in similar therapeutic areas as Puma, including breast cancer treatments, making them direct competitors.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad oncology portfolio that includes breast cancer treatments, competing with Puma's neratinib.
Novartis
NVS
Mkt Cap286.78B
Novartis offers treatments in the oncology sector, including breast cancer, directly competing with Puma's offerings.
Merck
MRK
Mkt Cap335.14B
Merck's extensive research and development in oncology, including breast cancer treatments, positions them as a competitor.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, with its growing oncology portfolio, competes in the same market as Puma Biotechnology.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb's focus on cancer drugs, including breast cancer, makes it a competitor to Puma.
AMGEN
AMGN
Mkt Cap224.63B
Amgen's oncology and hematology portfolio includes treatments that compete with Puma's cancer therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals, known for its innovative treatments, competes in the oncology space with Puma.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical division Janssen, offers oncology treatments that rival Puma's products.

About

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Show more...
CEO
Alan H. Auerbach
Employees
179
Country
United States
ISIN
US74587V1070

Listings

XNAS
US
PBYI
BOATS
BOATS
PBYI.BOATS

0 Comments

Share your thoughts

FAQ

What is Puma Biotechnology stock price today?▼
The current price of PBYI is $8.82 USD — it has decreased by -0.11% in the past 24 hours. Watch Puma Biotechnology stock price performance more closely on the chart.
What is Puma Biotechnology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Puma Biotechnology stocks are traded under the ticker PBYI.
Is Puma Biotechnology stock price growing?▼
PBYI stock has risen by +1.5% compared to the previous week, the month change is a +3.4% rise, over the last year Puma Biotechnology has showed a +53.93% increase.
What is Puma Biotechnology market cap?▼
Today Puma Biotechnology has the market capitalization of 455.29M
When is the next Puma Biotechnology earnings date?▼
Puma Biotechnology is going to release the next earnings report on October 29, 2026.
What were Puma Biotechnology earnings last quarter?▼
PBYI earnings for the last quarter are 0.16 USD per share, whereas the estimation was 0.04 USD resulting in a +300% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Puma Biotechnology revenue for the last year?▼
Puma Biotechnology revenue for the last year amounts to 228.37M USD.
What is Puma Biotechnology net income for the last year?▼
PBYI net income for the last year is 31.11M USD.
How many employees does Puma Biotechnology have?▼
As of August 17, 2026, the company has 179 employees.
In which sector is Puma Biotechnology located?▼
Puma Biotechnology operates in the Health & Wellness sector.
When did Puma Biotechnology complete a stock split?▼
Puma Biotechnology has not had any recent stock splits.
Where is Puma Biotechnology headquartered?▼
Puma Biotechnology is headquartered in LOS ANGELES, United States.